AGIO Quote, Financials, Valuation and Earnings

Dynavax Technologies Corp. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 28.38%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Dynavax Technologies Corp.'s return on equity of -7.65%.

Agios Pharmaceuticals, Inc. has a consensus price target of $36.75, signalling upside risk potential of 29.36%. On the other hand Dynavax Technologies Corp. has an analysts' consensus of $20.50 which suggests that it could grow by 33.03%. Given that Dynavax Technologies Corp. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Dynavax Technologies Corp. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.585% less volatile than S&P 500. In comparison Dynavax Technologies Corp. has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.879%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Dynavax Technologies Corp. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Dynavax Technologies Corp. quarterly revenues of $94.9M. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Dynavax Technologies Corp.'s net income of $26.9M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Dynavax Technologies Corp.'s PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 36.58x versus 6.44x for Dynavax Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Fulcrum Therapeutics, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 69.26%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Fulcrum Therapeutics, Inc.'s return on equity of -31.15%.

Agios Pharmaceuticals, Inc. has a consensus price target of $36.75, signalling upside risk potential of 29.36%. On the other hand Fulcrum Therapeutics, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 92.89%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.585% less volatile than S&P 500. In comparison Fulcrum Therapeutics, Inc. has a beta of 3.204, suggesting its more volatile than the S&P 500 by 220.383%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Fulcrum Therapeutics, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are larger than Fulcrum Therapeutics, Inc. quarterly revenues of --. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Fulcrum Therapeutics, Inc.'s net income of -$19.6M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Fulcrum Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 36.58x versus -- for Fulcrum Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of -19.69%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Moderna, Inc.'s return on equity of -30.18%.

Agios Pharmaceuticals, Inc. has a consensus price target of $36.75, signalling upside risk potential of 29.36%. On the other hand Moderna, Inc. has an analysts' consensus of $36.60 which suggests that it could grow by 6.71%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Moderna, Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Moderna, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.585% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is higher than Moderna, Inc.'s net income of -$200M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 36.58x versus 5.95x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 21.32%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Pfizer Inc.'s return on equity of 10.84%.

Agios Pharmaceuticals, Inc. has a consensus price target of $36.75, signalling upside risk potential of 29.36%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.585% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 36.58x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.